Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603

Watchlist Manager
Shijiazhuang Yiling Pharmaceutical Co Ltd Logo
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Watchlist
Price: 16.26 CNY -1.63% Market Closed
Market Cap: 27.2B CNY
Have any thoughts about
Shijiazhuang Yiling Pharmaceutical Co Ltd?
Write Note
Section:
 
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Shijiazhuang Yiling Pharmaceutical Co Ltd

Wall Street analysts forecast Shijiazhuang Yiling Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shijiazhuang Yiling Pharmaceutical Co Ltd is 21.37 CNY with a low forecast of 17.17 CNY and a high forecast of 24.38 CNY.

Lowest Forecast
Wall Street Target
17.17 CNY
6% Upside
Average Forecast
Wall Street Target
21.37 CNY
31% Upside
Highest Forecast
Wall Street Target
24.38 CNY
50% Upside
Lowest
Price Target
17.17 CNY
6% Upside
Average
Price Target
21.37 CNY
31% Upside
Highest
Price Target
24.38 CNY
50% Upside
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors:
Price Targets
ALM
Almirall SA
47% Upside
PFIZER
Pfizer Ltd
33% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
2% Upside
4506
Sumitomo Pharma Co Ltd
1% Downside
ALM
Almirall SA
47% Upside
PFIZER
Pfizer Ltd
33% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
2% Upside
4506
Sumitomo Pharma Co Ltd
1% Downside
BSEM
Biostem Technologies Inc
148% Upside
FULC
Fulcrum Therapeutics Inc
24% Upside

Revenue
Forecast

Revenue Estimate
Shijiazhuang Yiling Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's revenue is 16%. The projected CAGR for the next 3 years is 10%.

16%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Shijiazhuang Yiling Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's operating income is 17%. The projected CAGR for the next 3 years is 4%.

17%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Shijiazhuang Yiling Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's net income is 15%. The projected CAGR for the next 3 years is 12%.

15%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's stock price target?
Price Target
21.37 CNY

According to Wall Street analysts, the average 1-year price target for Shijiazhuang Yiling Pharmaceutical Co Ltd is 21.37 CNY with a low forecast of 17.17 CNY and a high forecast of 24.38 CNY.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's revenue is 16%. The projected CAGR for the next 3 years is 10%.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's operating income is 17%. The projected CAGR for the next 3 years is 4%.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Shijiazhuang Yiling Pharmaceutical Co Ltd's net income is 15%. The projected CAGR for the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.